Fed Regist. 2004 Oct 4;69(191):59132-4.
The Food and Drug Administration (FDA) is issuing a final rule to require the filing of a premarket approval application (PMA) or a notice of completion of a product development protocol (PDP) for the hip joint metal/polymer or ceramic/polymer semiconstrained resurfacing cemented prosthesis. The agency also is summarizing its proposed findings regarding the degree of risk of illness or injury designed to be eliminated or reduced by requiring the devices to meet the statute's approval requirements and the benefits to the public from the use of the devices. This action implements certain statutory requirements.
美国食品药品监督管理局(FDA)正在发布一项最终规则,要求为髋关节金属/聚合物或陶瓷/聚合物半约束型表面置换骨水泥假体提交上市前批准申请(PMA)或产品开发方案完成通知(PDP)。该机构还在总结其关于通过要求这些器械符合法规的批准要求来消除或降低的疾病或伤害风险程度的拟议调查结果,以及使用这些器械给公众带来的益处。此行动落实了某些法定要求。